Tesaro reports Phase I/II data for Zejula plus Keytruda combo in TNBC

Tesaro Inc. (NASDAQ:TSRO) reported data from 45 evaluable patients with triple-negative breast cancer (TNBC) in the Phase I/II TOPACIO (KEYNOTE-162) trial showing

Read the full 228 word article

User Sign In